1024 related articles for article (PubMed ID: 25237838)
21. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery.
Teixeira MC; Carbone C; Souto EB
Prog Lipid Res; 2017 Oct; 68():1-11. PubMed ID: 28778472
[TBL] [Abstract][Full Text] [Related]
22. Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery.
Rao S; Prestidge CA
Expert Opin Drug Deliv; 2016; 13(5):691-707. PubMed ID: 26866382
[TBL] [Abstract][Full Text] [Related]
23. Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: effect on skin permeation.
Clares B; Calpena AC; Parra A; Abrego G; Alvarado H; Fangueiro JF; Souto EB
Int J Pharm; 2014 Oct; 473(1-2):591-8. PubMed ID: 25102113
[TBL] [Abstract][Full Text] [Related]
24. Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.
Martins S; Sarmento B; Ferreira DC; Souto EB
Int J Nanomedicine; 2007; 2(4):595-607. PubMed ID: 18203427
[TBL] [Abstract][Full Text] [Related]
25. Chitosan based polymer-lipid hybrid nanoparticles for oral delivery of enoxaparin.
Dong W; Wang X; Liu C; Zhang X; Zhang X; Chen X; Kou Y; Mao S
Int J Pharm; 2018 Aug; 547(1-2):499-505. PubMed ID: 29859924
[TBL] [Abstract][Full Text] [Related]
26. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles.
Cheow WS; Hadinoto K
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):214-20. PubMed ID: 21439797
[TBL] [Abstract][Full Text] [Related]
27. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances.
Shreya AB; Raut SY; Managuli RS; Udupa N; Mutalik S
AAPS PharmSciTech; 2018 Dec; 20(1):15. PubMed ID: 30564942
[TBL] [Abstract][Full Text] [Related]
28. Polymeric Biomaterial and Lipid Based Nanoparticles for Oral Drug Delivery.
Dilnawaz F
Curr Med Chem; 2017; 24(22):2423-2438. PubMed ID: 27804879
[TBL] [Abstract][Full Text] [Related]
29. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives.
Mukherjee A; Waters AK; Kalyan P; Achrol AS; Kesari S; Yenugonda VM
Int J Nanomedicine; 2019; 14():1937-1952. PubMed ID: 30936695
[TBL] [Abstract][Full Text] [Related]
30. A special issue on Lipid-based delivery systems (liposomes, lipid nanoparticles, lipid matrices and medicines).
Souto EB
J Biomed Nanotechnol; 2009 Aug; 5(4):315-6. PubMed ID: 20055077
[No Abstract] [Full Text] [Related]
31. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.
Narang AS; Chang RK; Hussain MA
J Pharm Sci; 2013 Nov; 102(11):3867-82. PubMed ID: 24037829
[TBL] [Abstract][Full Text] [Related]
32. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ranpise NS; Korabu SS; Ghodake VN
Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
[TBL] [Abstract][Full Text] [Related]
33. Mucosal transfer of wheat germ agglutinin modified lipid-polymer hybrid nanoparticles for oral delivery of oridonin.
Liu Y; Liu J; Liang J; Zhang M; Li Z; Wang Z; Dang B; Feng N
Nanomedicine; 2017 Oct; 13(7):2219-2229. PubMed ID: 28539275
[TBL] [Abstract][Full Text] [Related]
34. Vesicle-like structure of lipid-based nanoparticles as drug delivery system revealed by molecular dynamics simulations.
Khalkhali M; Mohammadinejad S; Khoeini F; Rostamizadeh K
Int J Pharm; 2019 Mar; 559():173-181. PubMed ID: 30684596
[TBL] [Abstract][Full Text] [Related]
35. Recent advances and patents on solid lipid nanoparticles.
Sawant KK; Dodiya SS
Recent Pat Drug Deliv Formul; 2008; 2(2):120-35. PubMed ID: 19075903
[TBL] [Abstract][Full Text] [Related]
36. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers.
Shidhaye SS; Vaidya R; Sutar S; Patwardhan A; Kadam VJ
Curr Drug Deliv; 2008 Oct; 5(4):324-31. PubMed ID: 18855604
[TBL] [Abstract][Full Text] [Related]
37. Nanocarriers protecting toward an intestinal pre-uptake metabolism.
Suchaoin W; Bernkop-Schnürch A
Nanomedicine (Lond); 2017 Feb; 12(3):255-269. PubMed ID: 28093952
[TBL] [Abstract][Full Text] [Related]
38. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
Banerjee S; Pillai J
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
[No Abstract] [Full Text] [Related]
39. Albumin-Assisted Method Allows Assessment of Release of Hydrophobic Drugs From Nanocarriers.
Gil D; Frank-Kamenetskii A; Barry J; Reukov V; Xiang Y; Das A; Varma AK; Kindy MS; Banik NL; Vertegel A
Biotechnol J; 2018 Jan; 13(1):. PubMed ID: 28881095
[TBL] [Abstract][Full Text] [Related]
40. Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems.
Madkhali OA
Molecules; 2022 Feb; 27(5):. PubMed ID: 35268643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
